- Home
- MYI vs AQST Comparison
MYI vs AQST Comparison
Compare MYI & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MYI | AQST |
|---|---|---|
| Founded | 1992 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.5M | 809.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MYI | AQST |
|---|---|---|
| Price | $10.83 | $5.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.83 |
| AVG Volume (30 Days) | 256.7K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,397,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $52.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.32 | $2.12 |
| 52 Week High | $11.70 | $7.55 |
Technical Indicators
Market Signals| Indicator | MYI | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 44.71 |
| Support Level | $10.77 | $5.61 |
| Resistance Level | $10.92 | $6.44 |
| Average True Range (ATR) | 0.12 | 0.31 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 8.70 | 16.44 |
Price Performance
Historical ComparisonAbout MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.